Current situation of asthma-COPD overlap syndrome (ACOS) in Chinese patients older than 40 years with airflow limitation: rationale and design for a multicenter, cross-sectional trial (study protocol)

Jian Kang¹, Wanzhen Yao², Baiqiang Cai³, Ping Chen⁴, Xia Ling⁵, Hongyan Shang⁵

¹The First Hospital of China Medical University, Shenyang 110001, China; ²Department of Respiratory Medicine, Peking University Third Hospital, Beijing 100191, China; ³Department of Respiratory Medicine, Peking Union Medical College Hospital, Beijing 100730, China; ⁴Department of Respiratory Diseases, General Hospital of Shenyang Military Region, Shenyang 110016, China; ⁵Medical Affairs, AstraZeneca China, Shanghai 201203, China

Correspondence to: Prof. Jian Kang. The First Hospital of China Medical University, 155 Nanjing N Street, Heping, Shenyang 110001, China. Email: kangjian58@163.com.

Background: Asthma and chronic obstructive pulmonary disease (COPD) are the frequently occurring chronic airway diseases, and the overlapping syndrome observed in the majority of patients has been recently defined as asthma-COPD overlap syndrome (ACOS) by the Global Initiative for Chronic Obstructive Lung (GOLD, 2014) and Global initiative for Asthma (GINA, 2015). The proportion, features, and clinical practice of ACOS still remain elusive in China. We are conducting this multicenter, cross-sectional, observational study (NCT02600221) to investigate the distributions of chronic obstructive diseases in patients >40 years of age with chronic airflow limitation in China along with determination of the main clinical practice and features of these diseases. The study will also explore the factors that may influence the exacerbations and severity of ACOS in Chinese patients (>40 years of age).

Methods: A total of 2,000 patients (age, ≥40 years; either sex) who are clinically diagnosed as having asthma, COPD/chronic bronchitis/emphysema, or ACOS for at least 12 months with airflow limitation [post-bronchodilator forced expiratory volume in 1 second/forced vital capacity (FEV₁/FVC): <0.7] will be enrolled from approximately 20 sites in China between December 2015 and December 2016. The proportion of ACOS among patients older than 40 years based on GINA 2015 and GOLD 2014 definitions is the primary variable. Following were the secondary variables: the proportions of COPD and asthma among the patients, distributions of the severity of airflow limitation, distribution of groups according to GOLD 2011 group definition (A, B, C, D), and the distribution of medication by drug class in patients with ACOS, asthma, and COPD. Acute exacerbation history, hospitalization, and severity of ACOS as evaluated using COPD Assessment Test, Asthma Control Questionnaire-5, and Modified British Medical Research Council in patients with ACOS were also assessed.

Implications: This will be the first study to disseminate scientific knowledge on the current situation, main clinical practice, and features of ACOS, asthma, and COPD conditions in Chinese patients. The insights will be helpful in designing optimal management strategies for ACOS and redefining the healthcare development programs.

Keywords: Asthma-COPD overlap syndrome (ACOS); Global Initiative for Chronic Obstructive Lung (GOLD); Global initiative for Asthma (GINA); asthma; chronic obstructive pulmonary disease (COPD)
Introduction

In the continuum of chronic airway diseases, asthma and chronic obstructive pulmonary disease (COPD) are undoubtedly the common conditions considered as distinct clinical entities (1). However, a significant proportion of patients often present with overlapping conditions, which has now become a major health concern worldwide, accounting for approximately 15–25% of the obstructive airway diseases with patients experiencing worse outcomes compared with either of the conditions alone (2–4). Majorly, patients of a chronic airway disease present with a syndrome comprising symptoms of both asthma and COPD, the exact definition of which remains ambiguous (2). The Global Initiative for Chronic Obstructive Lung Disease (GOLD) proposed a term “asthma-COPD overlap syndrome” (ACOS) in 2014 to define this overlapping condition based on a detailed review of available literature and consensus (4).

To simplify, ACOS represents a condition of an asthmatic smoker who advances to chronic airflow obstruction with an unknown history of asthma, with symptoms of increased variability of airflow in association with incompletely reversible airflow obstruction (5). The prevalence of ACOS tends to increase with age in asthmatic individuals with estimates of >50% and in patients with COPD up to 23% at ages of ≥80 and >50 years, respectively (6). This reflects that ACOS develops gradually in patients with asthma and COPD (7,8). Furthermore, lack of specific biomarkers for ACOS makes the diagnosis more difficult (5).

Recurrent exacerbations, rapid disease progression, diminished health-related quality of life, rapidly deteriorating lung function, high co-morbidities, increased reversibility of airflow obstruction, eosinophilic bronchial and systemic inflammation, frequent hospitalization, and high mortality rates are frequently observed in such patients and they tend to receive an inconsistent healthcare management compared with either of the conditions alone (3-5,9,10). A stepwise approach for diagnosis and treatment of asthma, COPD, and ACOS is advised in the recent 2015 Global Initiative for Asthma (GINA) report along with differentiating features that identify and characterize ACOS (4). However, GINA did not clarify whether ACOS is a coexistence of asthma and COPD or a subtype of chronic airflow limitation. Few studies have been conducted to provide a fair understanding of ACOS manifested by both asthma and COPD symptoms (9,11,12). Studies from the western population have shown the prevalence of ACOS to be 1.8% when diagnosed using spirometry (13) and 2.7% when diagnosed based on self-reported or physician-diagnosed asthma and COPD (14). Furthermore, the prevalence of ACOS (3.2%) was lower than COPD (6.0%) or asthma alone (5.6%) in the United States (15), whereas the percentage of patients visiting emergency departments was high for ACOS than for COPD alone in Korea (16). This is associated with utilization of a large proportion of medical resources and, in turn, leading to higher healthcare costs because hospitalizations account to the largest expenditure, thereby imposing heavy economic burdens on patients (17). Previous research conducted in urban China, 2010, 2012, and 2013 China National Health and Wellness and internet-based Survey (NHWS) revealed a high incidence of ACOS in urban China, which was associated with the greatest co-morbidity burden (P<0.05) compared with asthma and COPD along with worse healthcare outcomes (18).

Methods

Study design

This is a multicenter, cross-sectional, observational study (NCT02600221) that will collect data from medical records or patient- or physician-reported data from approximately 20 sites from six geographical regions of China including northeast, north, south, east, west, and central China. The site numbers allocated to the six regions are generally
Table 1 Classification of severity of airflow limitation in COPD (classification based on post-bronchodilator FEV\textsubscript{i}, in patients with FEV\textsubscript{i}/FVC <0.7)

<table>
<thead>
<tr>
<th>Guideline</th>
<th>Disease severity</th>
<th>FEV\textsubscript{i}, range</th>
</tr>
</thead>
<tbody>
<tr>
<td>GOLD1</td>
<td>Mild</td>
<td>FEV\textsubscript{i} ≥80% predicted</td>
</tr>
<tr>
<td>GOLD2</td>
<td>Moderate</td>
<td>50%≤ FEV\textsubscript{i} &lt;80% predicted</td>
</tr>
<tr>
<td>GOLD3</td>
<td>Severe</td>
<td>30%≤ FEV\textsubscript{i} &lt;50% predicted</td>
</tr>
<tr>
<td>GOLD4</td>
<td>Very severe</td>
<td>FEV\textsubscript{i} &lt;30% predicted</td>
</tr>
</tbody>
</table>

GOLD, global initiative for chronic obstructive lung disease; FEV, forced expiratory volume; FVC, forced vital capacity.

consistent with the population (patients) distribution. Only tier-3 hospitals with GCP certificates will be selected as the study sites because those sites are well qualified to conduct this observational clinical study on ACOS. The planned study duration is from December 2015 to December 2016. This study is currently recruiting participants. Approximately 50–150 patients will be recruited from each site consecutively. That is, all eligible patients who consent to participate in this study will be recruited without any prejudice or preference from study personnel. All centers will have highly trained, experienced personnel. Investigators will be selected if they are respiratory physicians working in the respiratory department of tier-3 hospitals and are able to recruit and manage the expected number of patients with asthma, COPD, or ACOS in the stipulated time of 1 year. Physicians should have patient spirometric information available in the patient’s medical files [post-bronchodilator forced expiratory volume (post-BD FEV\textsubscript{i},% pred.) and post-bronchodilator forced vital capacity (post-BD FEV\textsubscript{i}/FVC)] and spirometries must be according to the guidelines (20). A total of 2,000 participants who meet the entry criteria will be enrolled in the study. This study will be carried out under routine clinical practice. Drug treatment or examinations will be determined by the physicians responsible for treatments and no investigational drugs will be used to treat asthma, COPD, or ACOS. Data about current medications and dosages used for treatment of the diseases or regarding concomitant medications will be collected at the visit. All the data pertaining to study outcomes will be recorded in CRF. The outcomes are expected to reflect the actual situation about ACOS in China.

**Study outcomes**

**Primary variable**

The proportion of ACOS among patients older than 40 years with airflow limitation (post-BD FEV\textsubscript{i}/FVC: <0.7) based on GINA and GOLD 2015 definitions was considered as the primary variable (4).

**Secondary variables**

Secondary variables included determination of the proportions of COPD and asthma among patients older than 40 years with airflow limitation based on GINA and GOLD 2015 definitions, respectively (4). The distributions of the severity of airflow limitation according to GOLD lung function grading based on post-BD FEV\textsubscript{i} in patients with ACOS, COPD, or asthma (Table 1), distribution of groups according to GOLD 2015 group definition (A, B, C, and D) in patients with ACOS or COPD (Table 2), and distribution of medication by drug class in patients with ACOS, asthma, or COPD were also determined. In addition, the proportion of ACOS patients with a previous diagnosis of asthma/
COPD/chronic bronchitis/emphysema was determined. Acute exacerbation history in 12 months before the visit (the number of exacerbations, severity of exacerbation (using systemic hormones/antibiotics/emergency/hospitalization), days of hospitalization or emergency room visit, and severity of ACOS as evaluated using COPD Assessment Test (CAT; mild, moderate, severe, and very severe), Asthma Control Questionnaire (ACQ-5; complete control, good control, and uncontrolled), and Modified British Medical Research Council (mMRC; 0, 1, 2, 3, and 4) were also assessed in patients with ACOS.

### Data analyses

#### Sample size justification

Considering that ACOS accounts for approximately 15–25% of the obstructive airway diseases and on the basis of previous studies, we expected that the proportion of patients with ACOS will be 20% among Chinese population (>40 years of age) with airflow limitation. With a sample size of 2,000 patients, the precision (half-length of 95% CI) of the ACOS proportion estimate will be 1.8%, which would adequately suffice the requirement of the study.

#### Statistical and analytical plans

Statistical analysis will be conducted based on the availability of data, and missing or incomplete data will be excluded from the analysis. Descriptive statistics will be used for analyzing primary and secondary outcomes. Continuous data will be expressed as number of patients, mean ± SD, or median. Categorical data will be expressed as frequency and percentages along with the 95% CI. Summary will be provided for ACOS, COPD, and asthma separately wherever applicable, as well as for overall. To explore the risk factors (continuous or categorical), univariate and multivariate Poisson regression analyses will be performed with grouped number of exacerbation as the dependent variable and the selected patient characteristics or/and clinical practices [gender, age, educational level, allergic history, smoking status, disease history (diagnosis/course), FEV₁ % pred., etc.] as the independent variables. For multivariate analysis, the selection of predicted factors will be processed by backward stepwise algorithm using a cutoff of 0.15. Similar risk factor analyses will be applied on the severity of patients with ACOS evaluated using CAT, ACQ-5, and mMRC. Statistical analyses will be performed using SAS Version 9.3 (SAS Institute Inc., Cary, NC); a P value of <0.05 will be used to indicate statistical significance.

### Study implications

Patients with ACOS comprise individuals who are usually smokers or nonsmokers with long-standing asthma that eventually develops to COPD. Concurrent doctor-diagnosed asthma and COPD have been reported in 15% to 20% of the patients. COPD gene and EPI-SCAN studies reported that approximately 13% and 17.4% of patients with COPD, respectively, have a history of asthma, and 22.8% of the patients with an FEV₁/FVC of <0.7 reported of having a previous diagnosis of asthma in the PLATINO study (5,20-27). This is the first multicenter, observational cross-sectional trial conducted to determine the current situation, main clinical practices, and features of ACOS, asthma, and COPD in Chinese patients (>40 years of age) with airflow limitation. Hence, the findings of this study may add significant data to the previous NHWS. In China, among all adults in the NHWS, 0.61% had ACOS (N=366), and 30.73% and 18.60% of those with asthma and COPD, respectively, had ACOS. Notably, patients with ACOS reported higher comorbidity burden and significantly worse health outcomes (13). Despite demonstrating clinically high significance, thorough understanding of the features and current clinical practice of ACOS remains elusive. There exists an unmet need on the

---

**Table 2 Combined COPD assessment**

<table>
<thead>
<tr>
<th>Patient category</th>
<th>Characteristics</th>
<th>Spirometric classification</th>
<th>Exacerbations (year)</th>
<th>Hospital admission</th>
<th>CAT</th>
<th>mMRC</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Low risk, less symptoms</td>
<td>GOLD 1–2</td>
<td>≤1</td>
<td>0</td>
<td>&lt;10</td>
<td>0–1</td>
</tr>
<tr>
<td>B</td>
<td>Low risk, more symptoms</td>
<td>GOLD 1–2</td>
<td>≤1</td>
<td>0</td>
<td>≥10</td>
<td>≥2</td>
</tr>
<tr>
<td>C</td>
<td>High risk, less symptoms</td>
<td>GOLD 3–4</td>
<td>≥2</td>
<td>≥1</td>
<td>&lt;10</td>
<td>0–1</td>
</tr>
<tr>
<td>D</td>
<td>High risk, High symptoms</td>
<td>GOLD 3–4</td>
<td>≥2</td>
<td>≥1</td>
<td>≥10</td>
<td>≥2</td>
</tr>
</tbody>
</table>

CAT, COPD assessment test; GOLD, global initiative for chronic obstructive lung disease; mMRC, modified medical research council.
data available regarding management of patients with ACOS as the patients are typically excluded from therapy trials for asthma or COPD. This indicates that the current data on efficacy of treatment may be irrelevant for the growing proportion of older patients with obstructive lung disease, and thus, the understanding and necessity to include ACOS in drug evaluation programs are demanded (24). Physicians seek clarity for differentiating asthma, COPD, and ACOS and land up in non-systematic use of varying diagnostic labels such as asthma with chronic bronchitis, chronic obstructive bronchitis, asthma with permanent obstruction, and COPD with a reversible component, which leads to a high uncertainty in understanding a case description (24). As a result of lack of diagnostic skills, delay in diagnostic testing, and underestimation of the symptom severity, patients become reluctant to consult the physician, which overall contribute toward underdiagnosis. Furthermore, the condition is aggravated and continued exposure to risk factors without adequate diagnosis will cause the condition to become worse. Understanding the clear diagnostic criteria and prospective validation of ACOS will be of great value in determining the optimal management strategies for ACOS.

Considering the continuous population increase in China and medical advancements, the overall death rate is slowed, but there is a rapid increase in the proportion of geriatric patients (28). Knowing that patients with ACOS are usually older in age, the possibility of the Chinese geriatric group having pulmonary diseases will also increase manifold. Currently, chronic respiratory diseases are the second leading cause of death in China (29). Studying the current status and management of ACOS in China may lead to identification of mechanistic pathways involved in it, which will lead in early identification of ACOS syndrome in patients and will subsequently result in providing appropriate care at proper time, thereby preventing the accelerated deterioration of lung function. Thus, the current study will prove to be very crucial in a growing country such as China and will add scientific knowledge on the current understanding of ACOS and management. Even though ACOS progresses as an indistinct entity and has clinical and pathophysiological features that often appear similar to those of asthma or COPD, we must emphasize the importance of the syndrome because of the following reasons:

- More frequent exacerbations than patients with COPD;
- Higher rates of dyspnea and wheezing (but not more cough and sputum), increased reversibility of airflow,
mechanisms with broader population groups with respiratory symptoms to strengthen the existing knowledge on ACOS.

Several researchers have been extensively studying on the differential diagnosis of ACOS from asthma and COPD. Xie et al. reported that asthmatic patients with a high emphysema index fulfill the features of ACOS, as described in the GINA and GOLD guidelines, suggesting quantitative CT measurements of emphysema in diagnosing ACOS (31). Furthermore, when the quality of life was studied as a feature of differential diagnosis, patients with ACOS reported higher disease impacts and dyspnea sensation not proportional to the severity of airflow limitation (32).

Given the fact that patients with ACOS are often excluded from asthma and COPD clinical trials, there is a lack of available evidence on the clinical features of ACOS. In our opinion, insights from the current study will aid in redefining the guidelines in China for optimum benefits in the management of ACOS as it exhibits greater risks of acute respiratory events in all age groups for both women and men (20).

Our study has several strengths: It adds significant data to the existing knowledge pertaining to not only ACOS but also asthma and COPD. It will be analyzing the records of physician-diagnosed diseases rather than patient-reported diagnoses and outcomes, which will depict real-world situation of China. Moreover, this is the first observational study to detect the ACOS situation in China conducted across 20 sites, which will depict the current status of ACOS and will improve the knowledge of physicians. Exacerbation rates will be analyzed by using Poisson regression model, which is the recommended method for analyzing exacerbations (33). Nevertheless, our study also has a limitation of being a non-interventional trial, because of which, not all variables may be collected in all the enrolled patients.

The current treatment guidelines provide scant evidence for the management of ACOS in patients (34); the outcomes of current study may be of prime interest to physicians in defining the clinical features of ACOS, which may in turn aid in deciding effective treatment strategies and improving the clinical outcomes. The present study will also consider the key clinical features defined by the Spanish guideline for COPD (GesEPOC) (35) and the ACOS consensus statement (36) for a post-hoc analysis.

In summary, the findings may provide a comprehensive understanding of significant clinical impact depicted by ACOS and will emphasize the need for clear diagnostic criteria to provide the optimal and cost-effective management approaches for patients with ACOS.

Acknowledgements

This study was funded by AstraZeneca Co Ltd. The authors thank Dr. Amit Bhat (Indegene Pvt Ltd, Bangalore) for providing necessary writing assistance and editorial support toward the development of the manuscript, funded by AstraZeneca.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The study protocol was approved by the institutional ethics committees of: (I) The First Affiliated hospital of China medical university [Approval ID: (2016)2015-142-2]; (II) Shengjing Hospital (China Medical University) (Approval ID: 2015PS324K); (III) Peking University Third Hospital (Approval ID: 2015-73-QT-HXK); (IV) West China Hospital, Sichuan University [Approval ID: 2015(295)]; (V) First Affiliated Hospital of Guangzhou Medical College (Approval ID: 2015-68); (VI) Shanghai Jiaotong University School of Medicine Ruijin Hospital [Approval ID: 2015(84)]; (VII) Beijing Union Medical College Hospital of Chinese Academy of Medical Sciences (Approval ID: B153); (VIII) Beijing Chaoyang Hospital, Capital University of Medical Sciences (Approval ID: 2015-2); (IX) Fudan University, East China Hospital (Approval ID: 20150239); (X) Henan Provincial People’s Hospital [Approval ID: 2015(37)]; (XI) First Affiliated Hospital of Xi’an Jiaotong University [Approval ID: XJTU1AF2015LSY-65]; (XII) General Hospital of Tianjin Medical University [Approval ID: IRB2015-103-01]; (XIII) Second Affiliated Hospital of Zhejiang University Medical College (Approval ID: 2015-083); (XIV) General Hospital of Chinese PLA Shenyang Military Region [Approval ID: (2015)38]; (XV) Chinese People’s Liberation Army 202 Hospital (Approval ID: 202H2016PJ001); (XVI) The First Affiliated Hospital of Sun Yat-sen University (Approval ID: 2016019); (XVII) Affiliated Hospital of Inner Mongolia Medical University [Approval ID: 2015(007)]; (XVIII) Hainan Provincial People’s Hospital [Approval ID: (2016)10]; (XIX) Second Affiliated Hospital of the Third Military Area of Chinese People’s Liberation Army (Approval ID: 2016023); (XX) Second Xiangya Hospital of Central South University [Approval ID: 2016(017)].
References


